Horizon Pharma soars as OPTIC trial meets all endpoints

Horizon Pharma (Nasdaq: HZNP) yesterday announced positive top-line results from its Phase III confirmatory trial evaluating teprotumumab (OPTIC) for the treatment of active thyroid eye disease (TED), with the news sending the firm’s rocketing 26.8% to $27.71 by mid-day trading.

The study met its primary endpoint, showing more patients treated with teprotumumab compared with placebo had a meaningful improvement in proptosis, or bulging of the eye: 82.9% of teprotumumab patients compared to 9.5% of placebo patients achieved the primary endpoint of a 2 mm or more reduction in proptosis (p<0.001). Proptosis is the main cause of morbidity in TED. All secondary endpoints were also met and the safety profile was consistent with the Phase II study of teprotumumab in TED.

BLA filing expected mid-2019